Analysts think SPRO stock price could increase by 433%
Jul 30, 2024, 6:26 AM
-4.53%
What does SPRO do
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focuses on developing treatments for bacterial infections, including multi-drug resistant infections, and rare diseases. Key pipeline candidates include Tebipenem HBr for complicated urinary tract infections, SPR720 for non-tuberculous mycobacterial infections, and SPR206 for MDR Gram-negative bacterial infections in hospitals.
4 analysts think SPRO stock price will increase by 433.10%. The current median analyst target is $7.65 compared to a current stock price of $1.44. The lowest analysts target is $7.07 and the highest analyst target is $8.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
